A series of CRBN-mediated AR PROTACs, which combine a tetramethylcyclobutane-based AR antagonist with the TD-106 CRBN binder, were developed and evaluated by Akshay D. Takwale et al. for the treatment of metastatic castration-resistant prostate cancer. This evidence concerns the gene AR and prostate carcinoma.